The Effect of 25% Less Patients in a Phase Three Trial

A drug company can get the same statistical power by enrolling 25% fewer people in their study, specifically in the placebo arm. If you're talking about a large phase three trial, reducing the size of the control group by 25%. That might mean like 100 fewer patients that you need to actually recruit and enroll in your study. It also just takes a long time to find people who are willing to participate.